Changzhou Qianhong Biopharma: Summary of Half-Year Report in 2024.
Changzhou Qianhong Biopharma: Interim financial statements.
Changzhou Qianhong Biopharma: Announcement of Board of Directors' resolution for semi-annual report.
Changzhou Qianhong Biopharma: Financial Report for the first half of 2024.
Changzhou Qianhong Biopharma: Announcement on the Extension of the Term of the Company's 2022 Core Employee Stock Ownership Plan
Changzhou Qianhong Biopharma: Half-year report for the year 2024.
Changzhou Qianhong Biopharma: Summary table of non-operating funds utilization and other related funds flow for the first half of the year.
Changzhou Qianhong Biopharma: Changzhou Qianhong Biopharma: Performance Forecast for the First Half of 2024.
Changzhou Qianhong Biopharma: 2023 Equity Distribution Implementation Notice
Changzhou Qianhong Biopharma: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Changzhou Qianhong Biopharma: Legal Opinion of Beijing Dacheng (Nanjing) Law Firm on the 2023 Annual General Meeting of Shareholders of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
Changzhou Qianhong Biopharma: 002550 Qianhong Pharmaceutical performance briefing, roadshow event information 20240509
Changzhou Qianhong Biopharma: Announcement on holding an online briefing session on the 2023 Annual Report
Changzhou Qianhong Biopharma: 002550 Qianhong Pharmaceutical Research Activity Information 20240426
Changzhou Qianhong Biopharma: 2024-023 Qianhong Pharmaceutical: Announcement on the company's profit distribution in 2023
Changzhou Qianhong Biopharma: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Changzhou Qianhong Biopharma: 2023 Self-inspection Form for the Implementation of the Company's Internal Control Rules
Changzhou Qianhong Biopharma: Notice of Annual General Meeting of Shareholders
Changzhou Qianhong Biopharma: Announcement of Board Resolutions
Changzhou Qianhong Biopharma: The Board's Special Opinions on Evaluating the Independence of Independent Directors
No Data